This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

A multi-center randomized proof-of-concept clinical trial applying ¹⁸FFDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer’s disease


Tzimopoulou, Sofia, Cunningham, Vincent J., Nichols, Thomas E., Searle, Graham, Bird, Nick P., Mistry, Prafull, Dixon, Ian J., Hallett, William A., Whitcher, Brandon, Brown, Andrew P., Zvartau-Hind, Marina, Lotay, Narinder, Lai, Robert Y. K., Castiglia, Mary, Jeter, Barbara, Matthews, Julian C., Chen, Kewei, Bandy, Dan, Reiman, Eric M., Gold, Michael, Rabiner, Eugenii A., Matthews, Paul M.


Journal Of Alzheimer's Disease: JAD, Volume: 22, No.: 4, Pages.: 1241-1256

Year of Publication



Here we report the first multi-center clinical trial in Alzheimer’s disease (AD) using fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) measures of brain glucose metabolism as the primary outcome. We contrasted effects of 12 months treatment with the PPARγ agonist Rosiglitazone XR versus placebo in 80 mild to moderate AD patients. Secondary objectives included testing for reduction in the progression of brain atrophy and improvement in cognition. Active treatment was associated with a sustained but not statistically significant trend from the first month for higher mean values in Kiindex and CMRgluindex, novel quantitative indices related to the combined forward rate constant for [18F]FDG uptake and to the rate of cerebral glucose utilization, respectively. However, neither these nor another analytical approach recently validated using data from the Alzheimer’s Disease Neuroimaging Initiative indicated that active treatment decreased the progression of decline in brain glucose metabolism. Rates of brain atrophy were similar between active and placebo groups and measures of cognition also did not suggest clear group differences. Our study demonstrates the feasibility of using [18F]FDG-PET as part of a multi-center therapeutics trial. It suggests that Rosiglitazone is associated with an early increase in whole brain glucose metabolism, but not with any biological or clinical evidence for slowing progression over a 1 year follow up in the symptomatic stages of AD.;


aged, aged, 80 and over, alzheimer disease, atrophy, brain, brain mapping, disease progression, double-blind method, drug effects, drug therapy, female, fluorodeoxyglucose f18, glucose, humans, magnetic resonance imaging, male, metabolism, middle aged, radionuclide imaging, rosiglitazone, therapeutic use, thiazolidinediones, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Non randomised controlled trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions